P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA

Bibliographic Details
Main Authors:	Wenjing Luo, Chenggong LI, Yinqiang Zhang, Xindi Wang, Zhuolin Wu, Haiming Kou, Cong Lu, Danying Liao, Zejian Chen, Caiqin Chen, Lijun Wu, Wei Xiong, Jun Deng, Yu Hu, Heng Mei
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972460.43253.39

Similar Items

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
by: Yinqiang Zhang, et al.
Published: (2023-04-01)

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
by: Chenggong Li, et al.
Published: (2023-01-01)

Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
by: Vita Golubovskaya, et al.
Published: (2021-02-01)

P1404: IL-10 PLUS THE EASIX SCORE PREDICT BLEEDING EVENTS AFTER ANTI-CD19 CAR T-CELL THERAPY
by: Xindi Wang, et al.
Published: (2023-08-01)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
by: Yanlong Liu, et al.
Published: (2022-08-01)

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
by: Ming Shi, et al.
Published: (2024-04-01)

Targeting CD22 for B-cell hematologic malignancies
by: Jia Xu, et al.
Published: (2023-10-01)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
by: Alexandra Dreyzin, et al.
Published: (2023-03-01)

The role of the tetraspanin CD37 in T and B cell responses
by: Wright, M, et al.
Published: (2005)

Targeting autophagy overcomes cancer‐intrinsic resistance to CAR‐T immunotherapy in B‐cell malignancies
by: Lu Tang, et al.
Published: (2024-03-01)

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
by: Yinqiang Zhang, et al.
Published: (2022-06-01)

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
by: Jie Chen, et al.
Published: (2023-07-01)

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
by: Justin C. Boucher, et al.
Published: (2023-12-01)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
by: Lijun Wu, et al.
Published: (2022-05-01)

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
by: Dina M Flink, et al.
Published: (2024-03-01)

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
by: Yunju Ma, et al.
Published: (2023-04-01)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
by: Lili Li, et al.
Published: (2022-12-01)

Plasma proteomic and metabolomic signatures of B‐ALL patients during CAR‐T cell therapy
by: Jianghua Wu, et al.
Published: (2023-03-01)

First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
by: Rupa Narayan, et al.
Published: (2024-03-01)

Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC.
by: Sheng, K, et al.
Published: (2009)

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
by: Jim Middelburg, et al.
Published: (2024-01-01)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
by: Eline van Diest, et al.
Published: (2023-01-01)

Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting
by: Shenhe Jin, et al.
Published: (2023-12-01)

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
by: Mary L. Faber, et al.
Published: (2023-08-01)

P1466: CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED T CELL MALIGNANCIES
by: Y. Zhang, et al.
Published: (2022-06-01)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
by: Fatih M. Uckun, et al.
Published: (2021-10-01)

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
by: C. Grandclément, et al.
Published: (2024-03-01)

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
by: Grandclément, C, et al.
Published: (2024)

Combination of a Novel Fusion Protein CD3εζ28 and Bispecific T Cell Engager Enhances the Persistance and Anti-Cancer Effects of T Cells
by: Feng Yu, et al.
Published: (2022-10-01)

294 Comparison of preclinical efficacy between CD19 CAR-T and CD3×CD19 bispecific antibody (blinatumomab)
by: Jun Huang, et al.
Published: (2023-11-01)

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
by: Jiahua Niu, et al.
Published: (2023-03-01)

The history of Thessaly, 1266-1393
by: Magdalino, P
Published: (1976)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
by: Peiling Zhang, et al.
Published: (2022-10-01)

Ferroptosis of CD163+ tissue-infiltrating macrophages and CD10+ PC+ epithelial cells in lupus nephritis
by: Qi Cheng, et al.
Published: (2023-07-01)

P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
by: C. Grandclement, et al.
Published: (2022-06-01)

1528 A phase I study of a novel BCMA×CD3 bispecific antibody EMB06 in relapsed or refractory multiple myeloma
by: Henry Miles Prince, et al.
Published: (2023-11-01)

P1393: HIGHER DOSE OF CD34+ CELLS PROMOTES EARLY RECONSTITUTION OF NATURAL KILLER CELLS AND IS ASSOCIATED WITH BETTER OUTCOMES AFTER UNMANIPULATED HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNAN
by: F. Zhao, et al.
Published: (2022-06-01)

The immune-metabolic crosstalk between CD3+C1q+TAM and CD8+T cells associated with relapse-free survival in HCC
by: Yanying Yang, et al.
Published: (2023-02-01)

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: C. Li, et al.
Published: (2022-06-01)